Core Insights - Sanuwave Health, Inc. has added its UltraMIST product line to Healogics iSupply, making it available to members including Wound Care Centers, home health agencies, and skilled nursing facilities [1][2] - The rollout of the UltraMIST system to Healogics iSupply members is planned for initial locations by the end of 2025 [2] - Collaboration with Healogics, a leader in wound care treatment and research, is seen as a significant opportunity for Sanuwave to provide innovative solutions to its members [3] Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [4] - The company offers a comprehensive wound care portfolio that aids in restoring normal healing processes through its patented energy transfer technologies [5] Industry Context - Healogics has been a leader in advanced wound care for nearly 30 years, partnering with hospitals and health systems to deliver specialized care for chronic wounds [6] - The organization is backed by the largest wound care outcomes database and the Wound Science Initiative, which supports research and sets new standards in healing [7]

Core Insights - The final rule for the 2026 Physician Fee Schedule by CMS aligns with the proposed rule and shows minimal changes from 2025 rates [1][2][3] - Reimbursement for the CPT code 97610 related to UltraMIST products remains largely unchanged, with payment rates for various treatment settings staying within $2-4 of 2025 levels [2][3] Summary by Sections Reimbursement Rates - The reimbursement for the 97610 code for UltraMIST products is expected to remain materially unchanged for 2026, with rates for physician offices, home visits, long-term care, and hospitals staying within $2-4 of 2025 rates [2] - Changes for 2026 are anticipated to be less than 1%, with many providers likely to see a slight increase in reimbursement [3] Company Response - In response to inquiries regarding UltraMIST reimbursement rates, the company provided an update confirming that the final 2026 rates are consistent with prior expectations [3] - The company plans to discuss these developments further during its third quarter earnings call [3]

Core Insights - Sanuwave Health, Inc. reported preliminary revenues of $11.4 million to $11.6 million for Q3 2025, marking the highest quarterly revenues in the company's history [1][2] - The revenue for Q3 2025 reflects an increase of 22% to 24% compared to Q3 2024 and a sequential increase of 12% to 14% from the previous quarter [1][2] - For the first nine months of 2025, revenue increased by 39% to 40% compared to the same period in 2024 [1] Revenue Guidance - The company has revised its 2025 annual revenue guidance from $48 million to $50 million down to $44 million to $46 million due to challenges faced in Q3 [3] - The Q3 performance was impacted by uncertainties surrounding proposed reimbursement changes in the wound care market, particularly affecting skin substitutes and grafts [3] Market Conditions - CEO Morgan Frank noted that the wound care market experienced a "wait and see" approach from providers, leading to delayed purchase decisions and reduced patient counts [3] - Despite these challenges, Sanuwave achieved record system sales in Q3, with September being the highest revenue month in the company's history [3] Reimbursement Insights - The UltraMIST reimbursement is not expected to be affected by potential changes in allograft reimbursement, with a slight increase anticipated for the 97610 code in 2026 compared to 2025 [4] - The current disruption in the market is viewed as a near-term challenge but also represents a significant future opportunity for the company [4] Upcoming Events - A conference call to discuss the Q3 results is scheduled for October 6, 2025, at 5:30 PM ET, with full Q3 results expected to be released around November 7, 2025 [5][6]

Q1 FY2024 May 10, 2024 Live Presentation Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1665712&tp_key=5ceebf04ab Replay Dial-in Information Toll Free: 1-844-512-2921 Toll/International: 1-412-317-6671 Replay Pin Number: 1155590 Friday, May 10, 2024, 8:30 AM (ET) Replay Expiry: June 3, 2024 2 Forward Looking Statements This presentation may contain "forward- ...